GLPG3667
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for GLPG3667, covering 2024-09-19 to 2025-12-23. Get the full timeline:
Most recent: Clinical Trial Update: A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis [Phase 2]